Skip to main content

Table 1 Clinical characteristics of ACLF and DLC patients according to the clinical outcome (90-d survival)

From: A new prognostic model based on serum apolipoprotein AI in patients with HBV-ACLF and acutely decompensated liver cirrhosis

Characteristics

Total (n = 561)

Survivors (n = 443)

Nonsurvivors (n = 118)

P Value

Age, (y)

51 (42–61)

51 (43–61)

51 (41–60)

0.86

Sex (male), n (%)

449 (80.0%)

348 (78.6%)

101 (85.6%)

0.089

HBV markers

    

HBeAg (+), n (%)

221 (39.4%)

184 (41.5%)

37 (31.4%)

0.044

HBV reactivation

    

Spontaneous reactivation, n (%)

382 (68.1%)

299 (67.5%)

83 (70.3%)

0.01

NUC cessation, n (%)

69 (12.3%)

47 (10.6%)

22 (18.7%)

NUC resistance, n (%)

15 (2.7%)

12 (2.7%)

3 (2.5%)

Without reactivation, admission for complication, n (%)

95 (16.9%)

85 (19.2%)

10 (8.5%)

Haematology

    

Hb (g/L)

120 (104–132)

120.0 (103.0-132.3)

119.0 (105.8–132.0)

0.99

Leukocytes (×109/L)

4.7 (3.0-6.6)

4.2 (2.9–6.1)

6.3 (4.5–9.2)

0.0001

Thrombocytes (×109/L)

75 (52–112)

73.0 (49.0-112.0)

80.0 (60.8–110.0)

0.14

INR

1.5 (1.3–1.8)

1.4 (1.2–1.7)

2.0 (1.7–2.5)

0.0001

Biochemistry

    

ALT (U/L)

77 (33–271)

63.0 (30.0-223.0)

117.0 (65.8-464.3)

0.0002

AST (U/L)

105 (48–230)

81.0 (43.0-185.0)

181.5 (110.5-445.8)

0.0001

TBIL (µmol/L)

136.6 (37.8-341.3)

86.5 (31.2-254.4)

424.0 (305.5-496.7)

0.0001

Albumin (g/L)

29 (25–33)

29 (26–33)

27 (24–31)

0.0001

Na (mmol/L)

138 (135–140)

139 (136–141)

135.0 (131.0-138.0)

0.0001

Cr (µmol/L)

69 (59–82)

69.0 (59.0–81.0)

72.0 (62.0-91.3)

0.068

Serum lipid profiles

    

HDL-C

0.50 (0.28–1.01)

0.66 (0.33–1.09)

0.27 (0.22–0.39)

0.018

LDL-C

1.50 (0.81–2.17)

1.63 (1.04–2.24)

0.74 (0.32–1.60)

0.0001

TG

1.00 (0.76–1.47)

1.00 (0.75–1.47)

1.02 (0.80–1.58)

0.99

TC

2.74 (1.91–3.57)

2.97 (2.19–3.80)

1.83 (1.18–2.45)

0.0001

ApoAI

0.54 (0.28–0.96)

0.67 (0.36–1.03)

0.21 (0.15–0.34)

0.0001

Comorbidities

    

Obesity

215 (38.3%)

162 (36.6%)

53 (44.9%)

0.098

NAFLD

32 (5.7%)

23 (5.2%)

9 (7.6%)

0.37

T2DM and IGT

113 (20.1%)

90 (20.3%)

23 (19.5%)

0.898

Hypertension

80 (14.3%)

65 (14.7%)

15 (12.7%)

0.766

Liver-related complications

    

Ascites, n (%)

432 (77.0%)

332 (74.9%)

100 (84.7%)

0.025

HRS, n (%)

62 (11.1%)

16 (3.6%)

46 (39.0%)

0.0001

Bacterial infection

253 (45.1%)

168 (37.9%)

85 (72.0%)

0.0001

HE(III-IV), n (%)

31 (5.5%)

7 (1.6%)

24 (20.3%)

0.0001

GEVB, n (%)

44 (7.8%)

32 (7.2%)

12 (10.2%)

0.29

Prognosis

    

MELD score

18.3 (12.6–23.8)

16.3 (11.9–21.1)

26.6 (23.4–29.6)

0.0001

  1. Notes. The values are presented as numbers (%) or medians (quartile range). Boldface P values indicate statistical significance
  2. Abbreviations: ACLF, acute-on-chronic liver failure; AD, acute decompensation; HBV, hepatitis B virus; NUC, nucleoside analogues; Hb, haemoglobin; INR, international normalized ratio; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBIL, total bilirubin; Cr, creatinine; TG, triglyceride; TC, total cholesterol, LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; apo AI, apolipoprotein AI; NAFLD, nonalcoholic fatty liver disease; T2DM, type 2 diabetes mellitus; IGT, impaired glucose tolerance; HRS, hepatorenal syndrome; HE, hepatic encephalopathy; GEVB, gastroesophageal variceal bleeding; MELD, model for end-stage liver disease
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X